Home » Mylan to Pay $465 Million Settlement for Classifying EpiPens as Generics
Mylan to Pay $465 Million Settlement for Classifying EpiPens as Generics
August 29, 2017
Mylan agreed to pay $465 million in a False Claims Act settlement over the classification of its EpiPen as a generic.
The Justice Department claimed the company classified the EpiPen as a generic to avoid paying rebates it owed to Medicaid. Using the classification, Mylan was able to hike EpiPen prices 400 percent between 2010 and 2016 while paying a fixed 13 percent rebate to Medicaid.
Sanofi, the initial whistleblower in the case, will receive approximately $38.7 million from the settlement.
Upcoming Events
-
21Oct